For years, investing in Nigerian pharma stocks was a massive risk, and even the most optimistic and daring investors only tucked their money into firms like Fidson or May & Baker for modest dividends and relative safety during economic downturns. 2025 flipped the script.
It was a year defined
```
Members Only
Login or create an account to continue
This article is available to registered BusinessDay readers. Please login if you already have an account, or create a new account to continue reading.
New to BusinessDay? Register now and start reading.
```
